ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 459

The Effect of Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Positivity on Drug Survival of Abatacept in Patients with Rheumatoid Arthritis in Routine Care: The Results from Turkbio Registry

Ihsan Ertenli1, Omer Karadag1, Yavuz Pehlivan2, Ediz Dalkilic3, Ahmet Mesut Onat4, Bunyamin Kisacik5, Gercek Can6, Servet Akar7, Sedat Capar8, Umut Kalyoncu1, Mustafa Ferhat Oksuz9, Emine Figen Tarhan7 and Nurullah Akkoc6, 1Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, 2Department of Rheumatology, Uludag University Faculty of Medicine, Bursa, Turkey, 3Department of Rhematology, Uludag University Faculty of Medicine, Bursa, Turkey, 4Rheumatology, Gaziantep University School of Medicine, Gaziantep, Turkey, 5Rheumatology Department, Gaziantep University School of Medicine, Gaziantep, Turkey, 6Department of Rheumatology, Dokuz Eylul University, Faculty of Medicine, Izmir, Turkey, 7Department of Internal Medicine, Division of Rheumatology, Izmir Katip Celebi University School of Medicine, Izmir, Turkey, 8Dokuz Eylül University Faculty of Statistics, Izmir, Turkey, 9Rheumatology, Uludag University Faculty of Medicine, Bursa, Turkey

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Abatacept, registry and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2015

Session Title: Rheumatoid Arthritis - Clinical Aspects Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Abatacept (ABA) is a
biological anti-rheumatic drug used in Rheumatoid Arthritis (RA). In TURKBIO,
Turkish Biologic Registry, data on patient characteristics, diagnosis, previous
treatment and outcomes of ABA have been collected since 2011. Drug retention is
a useful measure of effectiveness since it combines both clinical response and
tolerability. The objective of this study was to investigate the effect of
rheumatoid factor (RF) and Anti-Cyclic Citrullinated
Peptide (Anti-CCP) positivity on drug survival of ABA in clinical practice for
patients with RA.

Methods: By the end of May 2015, 266 patients received
intravenous and subcutaneous ABA from 5 participating centers of the TURKBIO
registry were included in the analysis. Demographic and clinical data including
age, sex, disease duration, drug retention rate and reasons for discontinuation
of drug were collected. Kaplan-Meier survival analysis was performed to
estimate the drug survival. Subgroups were compared by log-rank.

Results: Of the 266 patients receiving ABA, 83.8% were female
and median age was 55.0 years (range: 19.0-81.0). The median disease duration
was 9.0 years (range: 1.0 year-53.0 years). 72.6% of were treated with ABA as
first line biotherapy (n=193), 21.8% as second line (n=58) and 3.4% as third
line (n=9). The rate of RF positive patients was 54.1% and anti-CCP positive was
68.1% among the patients treated with ABA in the registry. Estimated drug
survival rates for ABA in 6th month, 1st year and 2nd
year were 76.1 %, 65.5% and 52.2% . Median drug survival
was 26 months. One-year drug survival of first line and >1st line
ABA treatment were 68.7% and 57.9%, respectively (p=0.084). There was a trend
for a higher one year drug survival rate among anti-CCP (+) patients as compared
to those who were anti-CCP (-) (73.1% versus 56.4%; p=0.087), whereas one-year
drug survival rates were very similar for RF (+) and RF (-) patients  at 63.4% and 64.8%, respectively (p=0.462) Drug
survival curves for RF (+)/(-) and Anti-CCP (+)/(-) groups are given in Figure
1 and 2, respectively.

Figure 1. Drug survival curve in RF (+) and (-) patients.

Figure 2.
Drug survival curve in anti-CCP (+) and (-) patients

Conclusion: One year drug survival rate of ABA among patients
enrolled in the TURKBIO registry is similar to those which has
been reported in some other European countries. One year drug survival rates
appear to be better among patients who are positive for anti-CCP, but not for
RF as compared to those who are negative for the corresponding antibodies,
which needs to be explored in future studies.


Disclosure: I. Ertenli, None; O. Karadag, None; Y. Pehlivan, None; E. Dalkilic, None; A. M. Onat, None; B. Kisacik, None; G. Can, None; S. Akar, None; S. Capar, None; U. Kalyoncu, None; M. F. Oksuz, None; E. F. Tarhan, None; N. Akkoc, None.

To cite this abstract in AMA style:

Ertenli I, Karadag O, Pehlivan Y, Dalkilic E, Onat AM, Kisacik B, Can G, Akar S, Capar S, Kalyoncu U, Oksuz MF, Tarhan EF, Akkoc N. The Effect of Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Positivity on Drug Survival of Abatacept in Patients with Rheumatoid Arthritis in Routine Care: The Results from Turkbio Registry [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/the-effect-of-rheumatoid-factor-and-anti-cyclic-citrullinated-peptide-positivity-on-drug-survival-of-abatacept-in-patients-with-rheumatoid-arthritis-in-routine-care-the-results-from-turkbio-registry/. Accessed July 1, 2022.
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-effect-of-rheumatoid-factor-and-anti-cyclic-citrullinated-peptide-positivity-on-drug-survival-of-abatacept-in-patients-with-rheumatoid-arthritis-in-routine-care-the-results-from-turkbio-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies